coPMLA-Me50H50

coPMLA-Me50H50 is a biodegradable, nontoxic, and nonimmunogenic copolymer derived from poly(β, L-malic acid) (PMLA) of microbial origin, where 50% of the pendant carboxyl groups are methylated. Developed by researchers at Cedars-Sinai Medical Center and the Universitat Politècnica de Catalunya, this copolymer is designed to serve as a versatile nanoconjugate platform for tumor-targeted drug delivery, particularly for brain and breast cancers. coPMLA-Me50H50 exhibits pH-dependent membranolytic activity, allowing it to disrupt endosomal membranes at acidic pH (such as pH 5.0) to facilitate cytoplasmic delivery of attached therapeutic payloads (such as chemotherapeutics, peptides, or oligonucleotides) while bypassing the plasma membrane.

Other names

coPMLA-Me(50)H(50)partially methylated poly(beta,L-malic acid) copolyester (50% methylated)poly(beta,L-malic acid) 50% methyl ester